De novo pyrimidine synthesis is a collateral metabolic vulnerability in NF2-deficient mesothelioma

Area of Science:

• Oncology
• Molecular Biology
• Metabolic Pathways

Background:

• Pleural mesothelioma (PM) is a deadly cancer with poor therapeutic options due to its complex genome and heterogeneity.
• The molecular basis of metabolic alterations in PM, especially how tumor suppressor gene (TSG) inactivation drives tumorigenesis, is not well understood.

Purpose of the Study:

• To investigate the molecular mechanisms of metabolic reprogramming in PM driven by TSG inactivation.
• To identify specific metabolic dependencies in NF2-deficient PM subtypes.

Main Methods:

• Integrated multi-omics analysis of pleural mesothelioma samples.
• Functional studies of NF2, YAP, CAD, and DHODH in cancer cell proliferation.
• In vitro and in vivo experiments to assess metabolic dependencies.

Main Results:

• NF2 loss of function defines a distinct PM subtype with heightened de novo pyrimidine synthesis.
• NF2-deficient PM cells exhibit critical dependence on this pathway for proliferation.
• NF2 loss activates YAP, upregulating key pyrimidine synthesis enzymes CAD and DHODH.

Conclusions:

• De novo pyrimidine synthesis is a critical metabolic vulnerability in NF2-deficient mesothelioma.
• Targeting this pathway offers a potential synthetic lethal therapeutic strategy for NF2-deficient PM.
• This research provides novel insights into PM metabolic reprogramming and potential interventions.